Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 239

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults

Open access
Kasamon, Yvette L., Bolaños-Meade, Javier, Prince, Gabrielle T., Tsai, Hua-Ling, McCurdy, Shannon R., Kanakry, Jennifer A., Rosner, Gary L., Brodsky, Robert A., Perica, Karlo, Smith, B. Douglas, Gladstone, Douglas E., Swinnen, Lode J., Showel, Margaret M., Matsui, William H., Huff, Carol Ann, Borrello, Ivan, Pratz, Keith W., McDevitt, Michael A., Gojo, Ivana, Dezern, Amy E., Shanbhag, Satish, Levis, Mark J., Luznik, Leo, Ambinder, Richard F., Fuchs, Ephraim J., Jones, Richard J. · 2015 · Journal of Clinical Oncology

Abstract

Purpose: Recent advances in nonmyeloablative (NMA), related HLA-haploidentical blood or marrow transplantation (haplo-BMT) have expanded the donor pool. This study evaluated the effect of age on NMA haplo-BMT outcomes in patients age 50 to 75 years. Patients and Methods: A retrospective analysis was performed of 271 consecutive patients with hematologic malignancies, age 50 to 75 years, who received NMA, T-cell–replete haplo-BMT with high-dose post-transplantation cyclophosphamide. Results: The median age was 61 years, with 115 patients (42%) age 50 to 59, 129 (48%) age 60 to 69, and 27 (10%) age 70 to 75 years. Overall, 84% of patients had intermediate- or high-/very high–risk disease. The 6-month probabilities of grade 3 or 4 acute graft-versus-host disease (GVHD) and nonrelapse mortality (NRM) were 3% and 8%, respectively. Patients in their 50s, 60s, and 70s had 6-month NRM probabilities of 8%, 9%, and 7%, respectively (P = .20). With a median follow-up of 4 years, corresponding 3-year progression-free survival probabilities were 39%, 35%, and 33% (P = .65), and corresponding 3-year overall survival probabilities were 48%, 45%, and 44% (P = .66). Three-year progression-free survival probabilities were 40% in acute myeloid leukemia (n = 65), 39% in aggressive non-Hodgkin lymphoma (n = 83), and 37% in indolent or mantle-cell lymphoma (n = 65). Older patient age was associated with a significantly higher risk of grade 2 to 4 acute GVHD but not grade 3 to 4 acute or chronic GVHD. No statistically significant associations were found between older age (relative to age 50 to 59 years or as a continuous variable) and NRM, relapse, or survival. Conclusion: NMA haplo-BMT with post-transplantation cyclophosphamide has encouraging safety and survival outcomes in patients age 50 to 75 years. In patients otherwise fit for BMT, the results support consideration of this approach despite advanced age.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.60.4777

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 239

Metadata

Authors
Kasamon, Y. L., Bolaños-Meade, J., Prince, G. T., Tsai, H.-L., McCurdy, S. R., Kanakry, J. A., Rosner, G. L., Brodsky, R. A., Perica, K., Smith, B. D., Gladstone, D. E., Swinnen, L. J., Showel, M. M., Matsui, W. H., Huff, C. A., Borrello, I., Pratz, K. W., McDevitt, M. A., Gojo, I., Dezern, A. E., Shanbhag, S., Levis, M. J., Luznik, L., Ambinder, R. F., Fuchs, E. J., & Jones, R. J.
Venue
Journal of Clinical Oncology
Published
2015-10-01
Volume
33
Issue
28
Pages
3152-3161
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2148995443
Cited by
239
References
2
FWCI
24.20
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. https://app.cochat.ai/papers/10.1200/jco.2014.60.4777
The paper
Kasamon, Y. L., Bolaños-Meade, J., Prince, G. T., Tsai, H.-L., McCurdy, S. R., Kanakry, J. A., Rosner, G. L., Brodsky, R. A., Perica, K., Smith, B. D., Gladstone, D. E., Swinnen, L. J., Showel, M. M., Matsui, W. H., Huff, C. A., Borrello, I., Pratz, K. W., McDevitt, M. A., Gojo, I., . . . Jones, R. J. (2015). Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.60.4777

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.